OneSource Specialty Pharma Ltd (ONESOURCE)
₹1,563.00
Mkt cap
₹17,924 Cr
P/E ratio
1,567.00
P/B
3.03
Div yield
0.00%
ROE
−1.09%
ROCE
0.59%
EPS (TTM)
₹1.00
Book value
₹516
52W range
1,057–1,925
Sector
Healthcare
Price history
Previous close
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio logical drug products in various injectable formats. It also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics [1]
NSE ONESOURCEBSE 544292
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthHigh
TechnicalsNeutral
52-week range
−18.81% from high₹1,563
₹1,057+47.87% from low₹1,925
Current
₹1,563.00
Prev close
₹1,569.60
Day
−0.42%
Price performance
1D
+0.97%
1W
+18.79%
1M
+0.09%
3M
−6.13%
6M
−10.08%
1Y
−13.91%
YTD
−13.14%
Financials
Revenue, profit & margin
P/E ratio
1,567.0×
ONESOURCE is 4,457% above the sector median of 34.4×
ONESOURCE1,567.0×
Sector median34.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 34 | 56 | 73 | 292 | 334 | 393 | 426 | 327 | 376 | 290 | 428 | 449 | 516 | |
| Expenses | 72 | 67 | 76 | 228 | 257 | 251 | 243 | 239 | 269 | 273 | 336 | 326 | 353 | |
| Operating Profit | -39 | -10 | -3 | 64 | 77 | 142 | 183 | 88 | 106 | 17 | 92 | 123 | 163 | |
| OPM % | -114% | -19% | -3.8% | 22% | 23% | 36% | 43% | 27% | 28% | 6% | 21% | 27% | 32% | |
| Other Income | -32 | -74 | 3 | -1 | -1 | -94 | 2 | 2 | 3 | -2 | 2 | -0 | -1 | |
| Interest | 25 | 26 | 20 | 42 | 45 | 46 | 33 | 27 | 34 | 38 | 23 | 31 | 35 | |
| Depreciation | 18 | 20 | 20 | 68 | 68 | 69 | 68 | 68 | 70 | 70 | 72 | 72 | 75 | |
| Profit before tax | -114 | -130 | -40 | -47 | -37 | -67 | 83 | -4 | 6 | -93 | -0 | 20 | 53 | |
| Tax % | 0% | 0% | 0% | -88% | 12% | 4% | -19% | -96% | -83% | -5% | -1,630% | -23% | -9% | |
| Net Profit | -114 | -130 | -40 | -6 | -42 | -69 | 98 | -0 | 10 | -89 | 5 | 25 | 57 | |
| EPS in Rs | -6.02 | 8.61 | -0.02 | 0.92 | -7.74 | 0.40 | 2.18 | 5.01 | ||||||
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.12% · closed higher next day 2 of last 9
| Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26† | Q1FY27 | Q2FY27 | |
|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 10 Feb '25◦ | 29 Jan '25◦ | 5 May '25◦ | 4 Aug '25◦ | 11 Nov '25◦ | 23 Jan '26◦ | 13 May '26 | 24 Jul '26◦ | 27 Oct '26 |
| Earnings day | −2.22% | +0.85% | −1.92% | −1.16% | +0.33% | −19.62% | −2.21% | +2.12% | +13.78% |
| +1 day | −5.24% | −1.77% | −1.54% | −2.12% | −1.49% | −19.36% | −0.56% | +4.68% | +12.90% |
| +5 days | −11.89% | −3.51% | −0.61% | −0.94% | −2.78% | −17.79% | +2.03% | −5.65% | — |
| +15 days | −7.64% | −17.18% | +7.25% | −3.28% | −5.92% | −9.58% | +0.42% | −5.79% | — |
| +30 days | +11.37% | −6.38% | +30.81% | −3.02% | −1.66% | +2.88% | −14.98% | −6.14% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202630.47%Promoter
Promoters30.47%0.01
FIIs19.45%0.26
DIIs24.20%0.83
Public25.86%1.09
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| OneSource Speci. | ₹1,563.00 | 1,566.75 | 17,924 | 0.00% | 57 | +464.73% | 516 | +37.39% | 0.59% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports2
Concall transcripts21
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Press Release / Media Release 30 Oct - OneSource receives USFDA EIR with VAI for Bengaluru SPD facility after June 2026 inspection.Announcement under Regulation 30 (LODR)-Newspaper Publication 28 Oct - Intimation about publication of newspaper advertisement - Extract of unaudited Standalone and Consolidated financial results for the quarter and half year ended September 30, 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 27 Oct - Audio recording of Q2 FY27 earnings call held October 27, 2026, made available on website.Announcement under Regulation 30 (LODR)-Press Release / Media Release 27 Oct - OneSource announced Q2FY27 results on Oct. 27, 2026: revenue ₹5,162m, EBITDA ₹1,633m, PAT ₹937m.Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 27 Oct - Intimation of allotment of 360 equity shares of Re.1/- each under ONESOURCE ESOP 2021 on October 27, 2026.